REGULATORY

• AZ’s Ticagrelor, BI’s Triple Combo to Take Another Stab to Clear MHLW Committee
  August 26, 2016

• MHLW Advisory Committee to Review Reversal Agent for Prazaxa on Sept. 7
  August 26, 2016

• MHLW Grants Orphan Status to Crizotinib, 3 Other Drugs
  August 26, 2016

• Innovative Drugs Are Not “Villain,” Kamoya Laments
  August 25, 2016

• Chuikyo Subcommittee Effectively Kicks Off Debates on FY2018 Reform, with Focus on Pricy Meds
  August 25, 2016

• Discussions on Opdivo’s Special Pricing Measure Get Underway at Chuikyo Subcommittee
  August 25, 2016

• After Taltz Given High Price, MHLW to Push Use of Other Psoriasis Drugs; Revision to Foreign Price Adjustment Eyed
  August 25, 2016

• MHLW to Set Up Dedicated Office for Antimicrobial Resistance: FY2017 Budget
  August 24, 2016

• MHLW to Seek 2 Billion Yen to Foster Healthcare Startups in FY2017
  August 24, 2016

• Chuikyo OKs Praluent, 8 Other APIs for Listing on Aug. 31
  August 24, 2016

• Basic Policies for JP 18th Edition Now Up for Public Comments
  August 23, 2016

• Japan to Target 95-100% SVR for Hep C, Compensated Cirrhosis in Revised 10-Year Strategy
  August 23, 2016

• MHLW to Seek Funding to Promote and Support Healthcare Startups in FY2017 Budget Request
  August 23, 2016

• MHLW to Seek Budgets to Develop Artificial Intelligence for Drug Discovery
  August 22, 2016

• Japanese Pharmacopoeia 17th Edition Now Available in English
  August 22, 2016

• G-CSF Preparations under PMDA Review for Anaphylaxis
  August 22, 2016

• MHLW Set to Defend “High-Level Investment” Credits for Key R&D Tax Break System in FY2017 Reform
  August 22, 2016

• Japan Approves 116 NMEs in FY2015, 37 on Priority Path: PMDA
  August 19, 2016

• AMED Taking Steps toward “Aggressive Intellectual Property Management”: IP Department Head
  August 18, 2016

• AMED Considers Giving Priority to Clinical Studies That Use Central IRBs: Official
  August 16, 2016

ページ

• « 先頭
• ‹ Prev
• …
• 273
• 274
• 275
• 276
• 277
• 278
• 279
• 280
• 281
• …
• Next ›
• 最終 »